SG Americas Securities
LPCN icon

SG Americas Securities’s Lipocine LPCN Stock Holding History

SG Americas Securities’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,134
Closed -$71K – 3438
2016
Q4 		$71K Buy
+1,134
New +$71.8K ﹤0.01% 2907
2016
Q3 		– Sell
-1,068
Closed -$55K – 3435
2016
Q2 		$55K Buy
+1,068
New +$165K ﹤0.01% 2448

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG Americas Securities's LPCN Position: Q1 2017 in Review

SG Americas Securities sold out of Lipocine (LPCN) in Q1 2017, closing a stake of 1,134 shares — an estimated $71K sold.

SG Americas Securities first reported a position in LPCN in Q2 2016 and held it in 2 quarters. The position peaked at $71K in Q4 2016. 50 funds tracked by Wall St. Rank hold LPCN as of Q1 2017.

  • SG Americas Securities reported no remaining Lipocine position as of Q1 2017 after selling out during the quarter.
  • SG Americas Securities sold 1,134 Lipocine shares in Q1 2017, an estimated $71K.
  • SG Americas Securities first reported a position in Lipocine in Q2 2016 and held it in 2 quarters.
  • SG Americas Securities's Lipocine position peaked at $71K in Q4 2016.
  • 50 funds tracked by Wall St. Rank held Lipocine as of Q1 2017.

Based on SG Americas Securities's 13F filing for Q1 2017, filed 10 May 2017.